Chief Executive Officer, Endovascular Engineering
Appears in 1 story
Leading commercial launch of the Hēlo platform
The FDA cleared two devices that together form a pulmonary embolism thrombectomy platform with integrated blood return. Endovascular Engineering's Hēlo system removes clots from the lungs while filtering and returning the patient's own blood, cutting median blood loss by 97% in the ENGULF trial.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
